



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY ¹

Last Trade:	82.23
Trade Time:	1:26 PM ET 06.27.2017
Change:	-0.69 (0.832%)
Day Range	81.27 - 83.86
52-Week Range	31.38 - 86.92
Volume	561,337
Market Cap. (\$M)	7,523.223
Shares Out (M)	91.490

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 06.26.2017 [Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis \(ISTH\) Congress](#)
- 06.26.2017 [Alnylam Reports New Positive Clinical Results for Givosiran \(ALN-AS1\), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias](#)
- 06.19.2017 [Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term](#)
- 06.12.2017 [Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office](#)
- 06.07.2017 [Alnylam Expands Third Annual "Helping Hands" Community Service Day Globally to Benefit 18 Organizations](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)
- 08.04.2016 [Quarterly Report \(10-Q\)](#)